Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.

Rohaan, Maartje W; Stahlie, Emma H A; Franke, Viola; Zijlker, Lisanne P; Wilgenhof, Sofie; van der Noort, Vincent; van Akkooi, Alexander C J; Haanen, John B A G

Rohaan, Maartje W; Stahlie, Emma H A; Franke, Viola; Zijlker, Lisanne P; Wilgenhof, Sofie; van der Noort, Vincent; van Akkooi, Alexander C J; Haanen, John B A G.

Afiliación

Rohaan MW; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Stahlie EHA; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Franke V; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Zijlker LP; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Wilgenhof S; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
van Akkooi ACJ; Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.
Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. j.haanen@nki.nl.

BMC Cancer ; 22(1): 851, 2022 Aug 04.

Article en En | MEDLINE | ID: mdl-35927710

Asunto(s)

Productos Biológicos; Melanoma; Nivolumab; Viroterapia Oncolítica; Neoplasias Cutáneas; Productos Biológicos/uso terapéutico; Ensayos Clínicos Fase II como Asunto; Herpesvirus Humano 1; Humanos; Melanoma/tratamiento farmacológico; Terapia Neoadyuvante; Nivolumab/uso terapéutico; Viroterapia Oncolítica/métodos; Calidad de Vida; Neoplasias Cutáneas/tratamiento farmacológico

Palabras clave

Early metastatic; High-risk; Immune checkpoint inhibitor; Melanoma; Neoadjuvant; Nivolumab; Resectable; Talimogene laherparepvec

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Cutáneas / Productos Biológicos / Viroterapia Oncolítica / Nivolumab / Melanoma Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google